Navigation Links
MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
Date:9/23/2008

GAITHERSBURG, Md., Sept. 23 /PRNewswire/ -- MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces that they will be conducting a Product Demonstration of the MaxCyte STX Scalable Transfection System on Thursday, September 25, 2008, at 10:00AM PDT, at the A/C/T Assays & Cellular Targets Conference in San Diego, California.

According to Dr. Madhusudan Peshwa, Vice President of Research and Development at MaxCyte, "The MaxCyte STX Scalable Transfection System can be used to transfect primary cells, cell lines, and stem cells with a range of molecules, including DNA plasmids, different types of RNA, proteins, etc., with very high efficiency. Over ten billion cells can be transfected in 30 minutes. This scale and capability can greatly improve the productivity of drug discovery laboratories. We are pleased to have the opportunity to demonstrate this technology at the A/C/T Meeting."

"We are very excited that the pharmaceutical industry views the MaxCyte STX technology as key to reducing drug discovery bottlenecks," says MaxCyte President and CEO, Doug Doerfler. "The MaxCyte STX can produce a large number of transfected cells in minutes compared to current time-consuming and inconsistent methods. Cells modified using the MaxCyte STX can be used on the research scale and in high-throughput screening assays. The faster you can get to the assay, the more compounds you can screen for biological activity, and the greater your likelihood of finding a successful drug candidate."

After the Product Demonstration, MaxCyte scientists will be available at the A/C/T Meeting to answer any technical questions relative to the performance and operation of the MaxCyte STX Scalable Transfection System.

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte has designed the MaxCyte STX Transfection System expressly for rapid, scalable, and reagent-free cell transfection for cell based assays, preclinical protein production, and other cell-based applications.

For more information, http://www.maxcyte.com/cell-based-screening.shtml.


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MaxCyte to Present at BIO-Europe Spring 2008 Conference
2. Binex and MaxCyte Collaborate on Cancer Immunotherapy Research
3. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
4. 2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expos 14-Year History
5. National Stem Cell Holding, Inc. (Ticker NHGI) Subsidiary Proteoderm, Inc. Debuts Cosmoceutical Line at the 2008 World Congress on Anti-Aging Medicine
6. Polymathic Analytical Labs Debuts at World's Largest Medical Design & Manufacturing Exhibition
7. PAL Health Technologies Debuts Xtremityscan System at Western Podiatric Medical Congress
8. Bluestar Silicones Debuts New Soft Elastomers at Medical Device & Manufacturing East Expo
9. International Center for Adult Stem Cell Education Debuts at Spinal Cord Injury Symposium in Greece
10. First-Ever Cancer and Careers Seminar Debuts in Orange County
11. Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 Australian-US drug discovery and development company, Novogen ... of a new Chairman, Mr John O,Connor , and ... James Garner , has also been formally ... Acting CEO, Mr Iain Ross , will resume his ... James Garner , has also been formally appointed to ...
(Date:2/4/2016)... ... 2016 , ... Shimadzu Scientific Instruments will showcase several new ... poster sessions, and present on the analysis of mycotoxins and medical cannabis at ... 10 at the Georgia World Congress Center in Atlanta, Georgia. , Attendees ...
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016 /PRNewswire/ ... "Company"), a biopharmaceutical company focused on the development and commercialization ... at the 18 th Annual BIO CEO & ... a.m. EST in New York, NY . ... will provide an update on the ongoing clinical trial of ...
(Date:2/4/2016)... 4, 2016 Sinovac Biotech Ltd. ("Sinovac" or ... of biopharmaceutical products in China , ... of directors received on February 4, 2016 a preliminary ... consortium comprised of PKU V-Ming ( Shanghai ... CICC Qianhai Development ( Shenzhen ) Fund ...
Breaking Biology Technology:
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
(Date:1/13/2016)... , January 13, 2016 /PRNewswire/ ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the addition ... Identification Market - Estimation & Forecast ...
(Date:1/7/2016)... , Jan. 7, 2016 This BCC Research ... for biometric technologies and devices, identifying newer markets and ... various types of biometric devices. Includes forecast from 2015 ... Identify newer markets and explore the expansion of the ... Examine each type of biometric technology, determine its current ...
Breaking Biology News(10 mins):